The advent of tumor-specific biomarkers has made major strides in advancing clinic diagnostic practices in a variety of tumors, including CEA and CA19-9 for colorectal cancer [18], AFP for hepatocellular carcinoma [19], and PSA for prostate cancer [20]. Here, AFP is linked to hepatocellular carcinoma.